oxonic acid has been researched along with Innate Inflammatory Response in 21 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyperuricemia (HUA) is induced by abnormal purine metabolism and elevated serum uric acid (UA) concentrations, and it is often accompanied by inflammatory responses and intestinal disorders." | 8.02 | Chlorogenic acid supplementation ameliorates hyperuricemia, relieves renal inflammation, and modulates intestinal homeostasis. ( Hu, N; Lin, Y; Wang, J; Wang, S; Wang, X; Zhang, B; Zhao, X; Zhou, X, 2021) |
| " Curcumin (CUR), a natural polyphenol component extracted from the rhizome of Curcuma longa, has been reported to treat various symptoms such inflammation disease, seems to be efficacious in hyperuricemia." | 7.91 | Curcumin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation in mice. ( Chen, Y; Duan, S; Hou, S; Li, C; Liang, J; Yuan, X, 2019) |
| " The effects and possible molecular mechanisms of astilbin on potassium oxonate-induced hyperuricemia mice were investigated in this study." | 7.83 | Astilbin improves potassium oxonate-induced hyperuricemia and kidney injury through regulating oxidative stress and inflammation response in mice. ( Chen, J; Wang, M; Zhang, N; Zhao, J, 2016) |
| "Hyperuricemia is the primary cause of gouty arthritis and other metabolic disorders." | 5.62 | Eggshell Membrane Ameliorates Hyperuricemia by Increasing Urate Excretion in Potassium Oxonate-Injected Rats. ( Kim, DS; Sung, YY, 2021) |
| "Inflammation is an important pathological feature of hyperuricemia, which in turn aggravates hyperuricemia." | 5.62 | Astaxanthin attenuated hyperuricemia and kidney inflammation by inhibiting uric acid synthesis and the NF-κ B/NLRP3 signaling pathways in potassium oxonate and hypoxanthine-induced hyperuricemia mice. ( Chen, Y; Liu, T; Yang, Z; Yuan, F; Zhang, L; Zhang, S; Zhou, X; Zhuang, J, 2021) |
| "Uric acid has promoted renal fibrosis and inflammation in experimental studies, but some studies have shown nephroprotective effects due to alleviated oxidative stress." | 4.31 | Moderate hyperuricaemia ameliorated kidney damage in a low-renin model of experimental renal insufficiency. ( Eräranta, A; Honkanen, T; Kurra, V; Lakkisto, P; Mustonen, J; Myllymäki, J; Paavonen, T; Pörsti, I; Riutta, A; Tikkanen, I, 2023) |
| " Hyperuricemia mice are induced via daily oral gavage of potassium oxonate and hypoxanthine." | 4.31 | Anti-Hyperuricemic, Nephroprotective, and Gut Microbiota Regulative Effects of Separated Hydrolysate of α-Lactalbumin on Potassium Oxonate- and Hypoxanthine-Induced Hyperuricemic Mice. ( Du, L; Shen, Y; Su, E; Wei, D; Xie, D; Xie, J, 2023) |
| "Hyperuricemia (HUA) is induced by abnormal purine metabolism and elevated serum uric acid (UA) concentrations, and it is often accompanied by inflammatory responses and intestinal disorders." | 4.02 | Chlorogenic acid supplementation ameliorates hyperuricemia, relieves renal inflammation, and modulates intestinal homeostasis. ( Hu, N; Lin, Y; Wang, J; Wang, S; Wang, X; Zhang, B; Zhao, X; Zhou, X, 2021) |
| " Curcumin (CUR), a natural polyphenol component extracted from the rhizome of Curcuma longa, has been reported to treat various symptoms such inflammation disease, seems to be efficacious in hyperuricemia." | 3.91 | Curcumin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation in mice. ( Chen, Y; Duan, S; Hou, S; Li, C; Liang, J; Yuan, X, 2019) |
| " The effects and possible molecular mechanisms of astilbin on potassium oxonate-induced hyperuricemia mice were investigated in this study." | 3.83 | Astilbin improves potassium oxonate-induced hyperuricemia and kidney injury through regulating oxidative stress and inflammation response in mice. ( Chen, J; Wang, M; Zhang, N; Zhao, J, 2016) |
| " trichocarpha, its ethyl acetate fraction and its main bioactive compounds could be useful to treat gouty arthritis by countering hyperuricemia and inflammation." | 3.78 | Pharmacological basis for use of Lychnophora trichocarpha in gouty arthritis: anti-hyperuricemic and anti-inflammatory effects of its extract, fraction and constituents. ( de Paula, CA; de Souza Filho, JD; de Souza, MR; Grabe-Guimarães, A; Pereira de Resende, ML; Saúde-Guimarães, DA, 2012) |
| "Hyperuricemia is the primary cause of gouty arthritis and other metabolic disorders." | 1.62 | Eggshell Membrane Ameliorates Hyperuricemia by Increasing Urate Excretion in Potassium Oxonate-Injected Rats. ( Kim, DS; Sung, YY, 2021) |
| "Inflammation is an important pathological feature of hyperuricemia, which in turn aggravates hyperuricemia." | 1.62 | Astaxanthin attenuated hyperuricemia and kidney inflammation by inhibiting uric acid synthesis and the NF-κ B/NLRP3 signaling pathways in potassium oxonate and hypoxanthine-induced hyperuricemia mice. ( Chen, Y; Liu, T; Yang, Z; Yuan, F; Zhang, L; Zhang, S; Zhou, X; Zhuang, J, 2021) |
| "A total of 83 advanced gastric cancer patients receiving biweekly docetaxel/S-1 treatment (DS) were included in the study." | 1.38 | Inflammation-based prognostic score predicts survival in patients with advanced gastric cancer receiving biweekly docetaxel and s-1 combination chemotherapy. ( Akiyama, H; Endo, I; Kimura, J; Kosaka, T; Kunisaki, C; Makino, H; Ono, HA; Oshima, T; Takagawa, R; Takahashi, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 9 (42.86) | 24.3611 |
| 2020's | 7 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Sung, YY | 1 |
| Kim, DS | 1 |
| Zhuang, J | 1 |
| Zhou, X | 2 |
| Liu, T | 1 |
| Zhang, S | 1 |
| Yuan, F | 1 |
| Zhang, L | 1 |
| Yang, Z | 1 |
| Chen, Y | 2 |
| ALRashdi, BM | 1 |
| Elgebaly, HA | 1 |
| Germoush, MO | 1 |
| Qarmush, MM | 1 |
| Azab, MS | 1 |
| Alruhaimi, RS | 1 |
| Ahmeda, AF | 1 |
| Abukhalil, MH | 1 |
| Kamel, EM | 1 |
| Arab, HH | 1 |
| Alzoghaibi, MA | 1 |
| Alotaibi, MF | 1 |
| Mahmoud, AM | 1 |
| Kurra, V | 1 |
| Eräranta, A | 1 |
| Paavonen, T | 1 |
| Honkanen, T | 1 |
| Myllymäki, J | 1 |
| Riutta, A | 1 |
| Tikkanen, I | 1 |
| Lakkisto, P | 1 |
| Mustonen, J | 1 |
| Pörsti, I | 1 |
| Xie, D | 1 |
| Shen, Y | 1 |
| Su, E | 1 |
| Du, L | 1 |
| Xie, J | 1 |
| Wei, D | 1 |
| Zhang, B | 1 |
| Zhao, X | 1 |
| Lin, Y | 1 |
| Wang, J | 1 |
| Wang, X | 1 |
| Hu, N | 1 |
| Wang, S | 1 |
| Li, H | 2 |
| Liu, X | 3 |
| Lee, MH | 1 |
| Li, Y | 1 |
| Li, Z | 1 |
| Wei, X | 1 |
| Ma, Y | 1 |
| Cheng, P | 1 |
| Jiao, R | 1 |
| Fang, J | 1 |
| Xing, Y | 1 |
| Tang, J | 1 |
| Wang, M | 2 |
| Li, T | 1 |
| Yang, TH | 1 |
| Yan, DX | 1 |
| Huang, XY | 1 |
| Hou, B | 1 |
| Ma, YB | 1 |
| Peng, H | 1 |
| Zhang, XM | 1 |
| Chen, JJ | 1 |
| Geng, CA | 1 |
| Li, C | 1 |
| Duan, S | 1 |
| Yuan, X | 1 |
| Liang, J | 1 |
| Hou, S | 1 |
| Zhou, Z | 1 |
| Dong, Y | 1 |
| Zhou, H | 1 |
| Liu, J | 1 |
| Zhao, W | 1 |
| Wang, MX | 1 |
| Liu, YL | 1 |
| Yang, Y | 1 |
| Zhang, DM | 1 |
| Kong, LD | 1 |
| Kasuga, A | 1 |
| Okano, N | 1 |
| Naruge, D | 1 |
| Kitamura, H | 1 |
| Takasu, A | 1 |
| Nagashima, F | 1 |
| Furuse, J | 1 |
| Zhao, J | 1 |
| Zhang, N | 1 |
| Chen, J | 1 |
| Chen, R | 1 |
| Shang, Y | 1 |
| Jiao, B | 1 |
| Huang, C | 1 |
| Tanigawa, T | 1 |
| Miyamoto, Y | 1 |
| Abe, M | 1 |
| Hasuo, T | 1 |
| Doiguchi, M | 1 |
| Sakamoto, F | 1 |
| Chikama, T | 1 |
| Takahashi, N | 1 |
| Wakuta, M | 1 |
| Nishida, T | 1 |
| de Souza, MR | 1 |
| de Paula, CA | 1 |
| Pereira de Resende, ML | 1 |
| Grabe-Guimarães, A | 1 |
| de Souza Filho, JD | 1 |
| Saúde-Guimarães, DA | 1 |
| Kunisaki, C | 1 |
| Takahashi, M | 1 |
| Ono, HA | 1 |
| Oshima, T | 1 |
| Takagawa, R | 1 |
| Kimura, J | 1 |
| Kosaka, T | 1 |
| Makino, H | 1 |
| Akiyama, H | 1 |
| Endo, I | 1 |
| Chang, YH | 1 |
| Bluestone, R | 1 |
| Hakoi, K | 1 |
| Hayashi, T | 1 |
| Ohmae, S | 1 |
| Besshi, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Three Arms, Randomized, Double-blind Controlled Trial of the Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia[NCT06084585] | 180 participants (Anticipated) | Interventional | 2023-10-23 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 other studies available for oxonic acid and Innate Inflammatory Response
| Article | Year |
|---|---|
Eggshell Membrane Ameliorates Hyperuricemia by Increasing Urate Excretion in Potassium Oxonate-Injected Rats.
Topics: Animals; Egg Shell; Humans; Hyperuricemia; Inflammation; Injections; Kidney; Kidney Function Tests; | 2021 |
Astaxanthin attenuated hyperuricemia and kidney inflammation by inhibiting uric acid synthesis and the NF-κ B/NLRP3 signaling pathways in potassium oxonate and hypoxanthine-induced hyperuricemia mice.
Topics: Animals; Antioxidants; Hyperuricemia; Hypoxanthine; Inflammation; Kidney; Male; Mice; Mice, Inbred I | 2021 |
A flavonoid-rich fraction of Monolluma quadrangula inhibits xanthine oxidase and ameliorates potassium oxonate-induced hyperuricemia in rats.
Topics: Animals; Catalase; Creatinine; Cytokines; Flavonoids; Hyperuricemia; Inflammation; Kidney; Molecular | 2022 |
Moderate hyperuricaemia ameliorated kidney damage in a low-renin model of experimental renal insufficiency.
Topics: Animals; Fibrosis; Hyperuricemia; Inflammation; Kidney; Kidney Diseases; Nephrectomy; Oxonic Acid; R | 2023 |
Anti-Hyperuricemic, Nephroprotective, and Gut Microbiota Regulative Effects of Separated Hydrolysate of α-Lactalbumin on Potassium Oxonate- and Hypoxanthine-Induced Hyperuricemic Mice.
Topics: Animals; Gastrointestinal Microbiome; Hyperuricemia; Hypoxanthines; Inflammation; Kidney; Lactalbumi | 2023 |
Chlorogenic acid supplementation ameliorates hyperuricemia, relieves renal inflammation, and modulates intestinal homeostasis.
Topics: Animals; Blood Urea Nitrogen; Chlorogenic Acid; Creatinine; Dietary Supplements; Gastrointestinal Mi | 2021 |
Vitamin C alleviates hyperuricemia nephropathy by reducing inflammation and fibrosis.
Topics: Animals; Antioxidants; Ascorbic Acid; Fibrosis; Hyperuricemia; Inflammation; Kidney Diseases; Male; | 2021 |
A novel IgG1 monoclonal antibody against xanthine oxidase alleviates inflammation induced by potassium oxonate in mice.
Topics: Allopurinol; Animals; Antibodies, Monoclonal; Antibody Affinity; Antioxidants; Creatinine; Cross Rea | 2018 |
Termipaniculatones A-F, chalcone-flavonone heterodimers from Terminthia paniculata, and their protective effects on hyperuricemia and acute gouty arthritis.
Topics: Anacardiaceae; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Chalcone; Dose-Re | 2019 |
Curcumin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Biomarkers; Curcumin; Cytokines; Dis | 2019 |
MiR-143-3p directly targets GLUT9 to reduce uric acid reabsorption and inflammatory response of renal tubular epithelial cells.
Topics: Animals; Base Sequence; Case-Control Studies; Chemokine CCL2; Disease Models, Animal; Gene Expressio | 2019 |
Nuciferine restores potassium oxonate-induced hyperuricemia and kidney inflammation in mice.
Topics: Animals; Aporphines; Carrier Proteins; Cell Line; Humans; Hyperuricemia; Inflammasomes; Inflammation | 2015 |
Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2015 |
Astilbin improves potassium oxonate-induced hyperuricemia and kidney injury through regulating oxidative stress and inflammation response in mice.
Topics: Animals; Carrier Proteins; Flavonols; Hyperuricemia; Inflammasomes; Inflammation; Janus Kinase 2; Ki | 2016 |
Lithospermic acid as a novel xanthine oxidase inhibitor has anti-inflammatory and hypouricemic effects in rats.
Topics: Allopurinol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Benzofurans; Depsid | 2008 |
[A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2009 |
Noninvasive direct detection of ocular mucositis by in vivo confocal microscopy in patients treated with S-1.
Topics: Aged; Antineoplastic Agents; Drug Combinations; Eye Diseases; Female; Humans; Inflammation; Male; Mi | 2009 |
Pharmacological basis for use of Lychnophora trichocarpha in gouty arthritis: anti-hyperuricemic and anti-inflammatory effects of its extract, fraction and constituents.
Topics: Acetates; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Asteraceae; Ethanol; Flavonoids; Hype | 2012 |
Inflammation-based prognostic score predicts survival in patients with advanced gastric cancer receiving biweekly docetaxel and s-1 combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; C-Reactive | 2012 |
Adjuvant polyarthritis. VI. Effect of oxonate-induced hyperuricemia on the development of acute inflammation, immune response and adjuvant arthritis.
Topics: Animals; Antibody Formation; Arthritis; Arthritis, Experimental; Cell Line; Diet; Edema; Immunity, C | 1981 |
[A 26-week oral repeated dose toxicity study of a new antineoplastic agent S-1 in rats].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Blood Chemical Analysis; Body Weight | 1996 |